Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (6930)	8/12/1998 6:06:00 PM
From: William L. Molair II	Read Replies (1) \| Respond to of 17367

DSMB meets again in Sept. Phase III for mengio ends the end of this year. Data Review for mengio Phase III trial complete in March 1999. Seven months seems like a long time to wait in this market; but, I've waited 19 months so far and I like our chances for success.

To: StockDoc who wrote (6930)	8/12/1998 6:42:00 PM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

Doc, Doc, Doc, Sepsis is like Cancer???? I liked how you slipped in gram positive example at this stage of the game. If you are serious about Xoma, how about doing some research on BPI especially rBPI21. You might want to check research also on BPI in regards to gram neg. sepsis. Let us concentrate on GRAM NEG. SEPTICEMIA and also synergy with antibiotics first THEN let us deal with gram positive events shall we? What else at this stage? Well why don't you look at phase II results on Hemo. Trauma trial. Might you turn ARDS into a niche group also?